Try
Pacira BioSciences, Inc.
PCRXUnited States
81 filed reports · 694 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
81 reports · Dec 2013 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 85 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 38 | 6,885 | Mar 2014 to Jun 2026 |
| Current · 8-KSEC EDGAR | 30 | 85 | Dec 2014 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 13 | 6,462 | Dec 2013 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 4, 2026 | 4 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 471 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 30, 2026 | 4 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 30, 2026 | 309 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 26, 2026 | 4 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 1,125 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 6, 2025 | 4 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 332 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 203 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 5, 2025 | 4 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 198 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 8, 2025 | 4 | Open |
Financial data
694 concepts · 13,432 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial663 concepts · 12,863 facts · Dec 2011 to Aug 2026
- Cost of revenue (US GAAP)73 · Dec 2011 to Jun 2026
- Net income loss73 · Dec 2011 to Jun 2026
- Revenue73 · Dec 2011 to Jun 2026
- Cash and cash equivalents at carrying value71 · Dec 2011 to Jun 2026
- Allocated share based compensation expense69 · Dec 2011 to Jun 2026
- Amortization of debt discount premium69 · Dec 2011 to Jun 2026
- Comprehensive income net of tax69 · Dec 2011 to Jun 2026
- Depreciation69 · Dec 2011 to Jun 2026
- Depreciation depletion and amortization69 · Dec 2011 to Jun 2026
- Goodwill (US GAAP)69 · Dec 2011 to Jun 2026
- Income tax expense benefit69 · Dec 2011 to Jun 2026
- Increase decrease in accounts receivable69 · Dec 2011 to Jun 2026
- Increase decrease in inventories69 · Dec 2011 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets69 · Dec 2011 to Jun 2026
- Investment income interest69 · Dec 2011 to Jun 2026
- Nonoperating income expense69 · Dec 2011 to Jun 2026
- Operating income loss69 · Dec 2011 to Jun 2026
- Other comprehensive income loss net of tax portion attributable to parent69 · Dec 2011 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax69 · Dec 2011 to Jun 2026
- Other nonoperating income expense69 · Dec 2011 to Jun 2026
- Payments to acquire property plant and equipment69 · Dec 2011 to Jun 2026
- Proceeds from stock options exercised69 · Dec 2011 to Jun 2026
- Research and development expense69 · Dec 2011 to Jun 2026
- Selling general and administrative expense69 · Dec 2011 to Jun 2026
Product5 concepts · 279 facts · Dec 2011 to Jun 2026
- Revenue273 · Dec 2016 to Jun 2026
- Discontinued operation gain loss from disposal of discontinued operation before income tax3 · Jun 2017 to Dec 2018
- Impairment of long lived assets held for use1 · Dec 2011
- Inventory write down1 · Dec 2017
- iovera°1 · Dec 2024
Segment19 concepts · 179 facts · Dec 2022 to Jun 2026
- Amortization of intangible assets14 · Dec 2022 to Jun 2026
- Reportable Segment14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Share based compensation14 · Dec 2022 to Jun 2026
- Other cost of operating revenue13 · Dec 2022 to Mar 2026
- Business combination contingent consideration arrangements change in amount of contingent consideration liability112 · Dec 2022 to Jun 2026
- Costs and expenses12 · Dec 2022 to Jun 2026
- Income tax expense benefit12 · Dec 2022 to Jun 2026
- Net income loss12 · Dec 2022 to Jun 2026
- Litigation settlement loss11 · Dec 2023 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest10 · Dec 2022 to Jun 2026
- Goodwill impairment loss8 · Dec 2022 to Dec 2025
- Impairment of intangible assets excluding goodwill8 · Dec 2022 to Dec 2025
- Nonoperating income expense8 · Dec 2022 to Jun 2026
- Litigation settlement gain7 · Dec 2023 to Dec 2025
- Gains losses on extinguishment of debt4 · Dec 2022 to Dec 2025
- Restructuring reserve accelerated depreciation3 · Dec 2022 to Dec 2024
- Disposal group not discontinued operation gain loss on disposal2 · Jun 2025 to Jun 2026
- Divestiture-related expenses1 · Jun 2026
Guidance3 concepts · 85 facts · Feb 2015 to Aug 2026
- Gross Margin Guidance60 · Feb 2015 to Aug 2026
- Revenue Guidance24 · Feb 2020 to Aug 2026
- Revenue Growth Guidance1 · Jan 2025
KPI1 concepts · 19 facts · Dec 2023 to Jun 2026
- Average Selling Price per Unit YoY Change19 · Dec 2023 to Jun 2026
Geography3 concepts · 7 facts · Sep 2023 to Dec 2025
- Massachusetts3 · Sep 2023 to Dec 2023
- U.S3 · Dec 2025
- Gain loss on termination of lease1 · Dec 2023
Segments
465 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis11 members · 252 facts
- Product43 · Dec 2017 to Jun 2026
- Royalty43 · Dec 2017 to Jun 2026
- Iovera38 · Jun 2018 to Jun 2026
- Bupivacaine Liposome Injectable Suspension29 · Dec 2019 to Jun 2026
- ZILRETTA29 · Dec 2019 to Jun 2026
- EXPARE Lbupivacaineliposomeinjectablesuspension24 · Dec 2017 to Sep 2023
- EXPAREL23 · Mar 2018 to Jun 2026
- Collaborative Licensing And Milestone Revenue13 · Jun 2020 to Dec 2023
- Iovera Member5 · Dec 2017 to Dec 2021
- Depo Cyte3 · Dec 2017 to Dec 2019
- Depo Cyteand Other Products2 · Mar 2018 to Mar 2019
Statement business segments1 member · 179 facts
- Reportable179 · Dec 2022 to Jun 2026
Product or serviceus-gaap:ProductOrServiceAxis4 members · 27 facts
- Depo Cyteand Other Products11 · Dec 2016 to Dec 2018
- EXPAREL11 · Dec 2016 to Dec 2018
- Depo Cyte4 · Jun 2017 to Dec 2018
- Depo Dur1 · Dec 2011
Statement geographical4 members · 7 facts
- MA4 · Sep 2023 to Dec 2023
- DE1 · Dec 2025
- GB1 · Dec 2025
- US1 · Dec 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 4, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.